Get the Stockscreener App
1.45
3.33%
-0.05
After Hours:
1.47
0.02
+1.38%
Telomir Pharmaceuticals Inc stock is traded at $1.45, with a volume of 168.53K.
It is down -3.33% in the last 24 hours and down -30.95% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$1.50
Open:
$1.5
24h Volume:
168.53K
Relative Volume:
0.06
Market Cap:
$43.16M
Revenue:
-
Net Income/Loss:
$-16.14M
P/E Ratio:
-2.6852
EPS:
-0.54
Net Cash Flow:
$-3.99M
1W Performance:
-2.68%
1M Performance:
-30.95%
6M Performance:
-62.92%
1Y Performance:
-74.38%
1-Day Range:
$1.45
$1.51
1-Week Range:
$1.41
$1.57
52-Week Range:
$1.12
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.45 | 45.99M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
What recovery options are there for Telomir Pharmaceuticals Inc.2025 Price Action Summary & Free Technical Pattern Based Buy Signals - Newser
Using Python tools to backtest Telomir Pharmaceuticals Inc. strategiesQuarterly Market Summary & Safe Capital Growth Trade Ideas - Newser
Key metrics from Telomir Pharmaceuticals Inc.’s quarterly dataWeekly Trade Summary & Weekly Hot Stock Watchlists - Newser
Statistical indicators supporting Telomir Pharmaceuticals Inc.’s strengthMarket Weekly Review & Low Risk Growth Stock Ideas - Newser
Can machine learning forecast Telomir Pharmaceuticals Inc. recoveryWeekly Profit Report & Daily Volume Surge Trade Alerts - Newser
Earnings visualization tools for Telomir Pharmaceuticals Inc.Portfolio Value Summary & AI Forecasted Stock Moves - Newser
Telomir Pharmaceuticals Inc. stock volume spike explained2025 Momentum Check & Fast Gain Stock Tips - Newser
Can swing trading help recover from Telomir Pharmaceuticals Inc. lossesTrade Analysis Report & Expert Curated Trade Setup Alerts - Newser
Real time social sentiment graph for Telomir Pharmaceuticals Inc.July 2025 Retail & Smart Allocation Stock Tips - Newser
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeriaan Ultra-Rare Genetic Disorder that Causes Rapid Aging - The Florida Times-Union
Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints - Bergen Record
What the charts say about Telomir Pharmaceuticals Inc. todayBreakout Watch & Step-by-Step Swing Trade Plans - Newser
Will Telomir Pharmaceuticals Inc. outperform the marketDollar Strength & Safe Investment Capital Preservation Plans - Newser
Telomir Pharmaceuticals Inc. stock trend forecastShort Setup & Accurate Buy Signal Alerts - Newser
What to expect from Telomir Pharmaceuticals Inc. in the next 30 daysJuly 2025 Recap & Capital Efficient Trade Techniques - Newser
Using economic indicators to assess Telomir Pharmaceuticals Inc. potentialJuly 2025 Summary & Expert Approved Momentum Trade Ideas - Newser
Is Telomir Pharmaceuticals Inc. still worth holding after the dip2025 Bull vs Bear & Stock Timing and Entry Methods - Newser
Developing predictive dashboards with Telomir Pharmaceuticals Inc. dataMarket Activity Recap & Free Fast Gain Swing Trade Alerts - Newser
Volatility clustering patterns for Telomir Pharmaceuticals Inc.Long Setup & Reliable Intraday Trade Alerts - Newser
Visual trend scoring systems applied to Telomir Pharmaceuticals Inc.Weekly Trend Report & Technical Entry and Exit Tips - Newser
Is Telomir Pharmaceuticals Inc. meeting your algorithmic filter criteriaMarket Risk Analysis & Low Risk High Reward Trade Ideas - Newser
Published on: 2025-08-16 23:11:59 - Newser
How to track smart money flows in Telomir Pharmaceuticals Inc.2025 Major Catalysts & Daily Volume Surge Trade Alerts - Newser
Technical analysis overview for Telomir Pharmaceuticals Inc. stockPortfolio Performance Report & Pattern Based Trade Signal System - Newser
Custom strategy builders for tracking Telomir Pharmaceuticals Inc.July 2025 Decliners & Weekly Market Pulse Updates - Newser
Telomir Pharmaceuticals Stock Price, Quotes and Forecasts - Benzinga
Is Telomir Pharmaceuticals Inc. forming a reversal patternTake Profit & Risk Controlled Stock Pick Alerts - Newser
Is a relief rally coming for Telomir Pharmaceuticals Inc. holdersTrade Ideas & Precise Buy Zone Tips - Newser
Is it too late to sell Telomir Pharmaceuticals Inc.Weekly Gains Summary & Technical Entry and Exit Tips - Newser
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):